Lanark

Sepsis is a serious condition caused by the bodys extreme response to an infection, leading to tissue and organ damage. This research compares two early treatment methods for sepsis immediately after hospital arrival, focusing on whether starting vasopressor medication right away or beginning with fluid therapy improves patient recovery and reduces complications. The study is a Phase 3 trial aimed at finding the best approach to improve outcomes for adults with septic shock. Participants are divided into two groups one receives a continuous peripheral vasopressor infusion of norepinephrine during the first 48 hours, while the other group receives standard care guided by UK NICE and Surviving Sepsis Campaign guidelines, which starts with intravenous fluids and adds vasopressors as needed. Both treatments follow local hospital protocols beyond the initial interventions. During the study, participants will be closely monitored for blood pressure, fluid volume, lactate levels, and other health indicators at multiple time points up to 90 days after randomization. Researchers will assess outcomes including hospital stay length, need for additional therapies like renal replacement or respiratory support, and overall survival. Quality of life and readmission rates will also be evaluated to understand the longer-term effects of the treatments.

Waldenstrf6ms macroglobulinaemia WM is a rare, slow-growing lymphoma that develops due to abnormal growth of white blood cells. This condition mainly affects older adults, with a median age of over 70 years. Current treatments often do not provide lasting responses and can have significant side effects. Researchers are evaluating a chemotherapy-free treatment option combining ibrutinib with rituximab RI to potentially improve treatment outcomes, reduce toxicity, and enhance quality of life compared to the existing chemotherapy regimen. The study compares two treatment groups for adults aged 18 and over with untreated WM. One group receives the experimental chemotherapy-free combination of ibrutinib and rituximab RI, while the control group is treated with the standard chemotherapy regimen of dexamethasone, rituximab, and cyclophosphamide DRC. Treatment cycles last up to six cycles, with response assessments after three cycles and at the end of treatment around 24 weeks. Participants in the RI group may continue with up to five years of ibrutinib alone after randomised treatment. Participants will have regular visits during treatment and then every three months for five years after stopping treatment. Annual follow-up for survival continues until the study ends, which is expected to last over nine years. Researchers will monitor treatment responses, progression-free survival, side effects, overall survival, quality of life using questionnaires, and other outcomes to assess the benefits and risks of the two therapies.